Chip talks with Dr. Toyin Ajayi, co-founder and CEO of Cityblock Health, which delivers value-based care to more than 100,000 Medicaid and dual-eligible members across ten states, many of them people of color managing chronic conditions. [AB1.1][AB1.2][MR1.3][AB1.4]Ajayi makes a pointed case: Roughly 60 percent of health care AI investment goes to billing, coding, and risk…
People who don’t have a trusted health care provider are more likely than people with one to believe or lean toward believing several common myths about vaccines, a new KFF Tracking Poll on Health Information and Trust reveals.
June has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, the American Medical Association, CMS and R1 RCM named new executives. There were also layoffs at organizations including ADC Therapeutics, Equip and UPMC. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on…
Health tech companies made several major funding announcements in June. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in June appeared first on MedCity News.
With CRISP Shared Services assuming operation of the state’s health information exchange, Mary Mayhew, president and CEO of the Florida Hospital Association, says the next phase is about giving providers access to comprehensive clinical information that follows patients across the continuum of care
The answer is provided by FDA’s 2025 Drug Trials Snapshots Summary Report. The report covers 46 novel drug approvals and roughly 26,000 participants across pivotal trials, organized by therapeutic area rather than a single aggregate narrative. Half (23 out of 46) of these approvals were for the treatment of rare or orphan diseases (i.e., diseases…
Kathy Saunders, senior vice president of revenue cycle management at Redefine, speaks about partnership with AI orchestration company Adonis
Using claims data from the 2023 Merative MarketScan Commercial Claims Database, this Peterson-KFF analysis describes the most common diagnoses for inpatient treatment and total associated costs, including patients’ out-of-pocket share.
Ipsen is acquiring Kartos Therapeutics to get navtemadlin, which has reached Phase 3 testing in the blood cancer myelofibrosis. The Kartos oral small molecule takes a novel approach to restoring the function of p53, a tumor-suppressing protein. The post Ipsen’s $450M Deal Brings Drug That Could Make a Standard Blood Cancer Therapy Better appeared first…
This news release highlights that a KFF analysis finds that 3.8 million Medicare beneficiaries met the criteria to be eligible for the new Medicare GLP-1 Bridge, based on claims data from 2023. The temporary program will provide coverage of three GLP-1 drugs used for weight reduction and weight management to eligible Medicare beneficiaries.